Klin Onkol 2003; 16(4): 187-192.
Summary: There is no standard for the chemotherapy of advanced gastric cancer. Due to supposed synergism between irinotecan and cisplatin the regimen for 2nd line treatment was designed: cisplatin 80 mg/m2, D1, irinotecan 200 mg/m2 D2 every 21 days. The indication criteria were as follows: histologically verified gastric cancer or the cancer of gastroesophageal junction, one prior chemotherapeutic regimen, PS 0-2, adequate hematological and biochemical parameters, no other contraindication for cisplatin. 13 patients, 8 males, 5 females, a mean age 49 years (2758), all pretreated with chemotherapy consisted of etoposide, leucovorine, 5-fluorouracil. Median number of cycles was 3 (1-7). 12 patients were evaluable for the response and adverse effects. CR was reached in 1 patient, PR in 4, SD in 6 and PD during therapy occurred in 1 patient. Time to progression has been evaluated in 7 patients who had progressed so far. The median is 4,5 months (2-7,5). One patient with complete response has been living 17 months so far with no signs of reccurence. Neutropenia G 3/4 developed in 6 patients with 1 episode of febrile neutropenia. Gastrointestinal adverse effects were mild. There was no death related to therapy. Chemotherapy appears to be effective with mild toxicity.
